Pulmonary Hypertension Overview And Treatment

20 Questions | Total Attempts: 610

SettingsSettingsSettings
Please wait...
Pulmonary Hypertension Overview And Treatment

This quiz discusses the pathophysiology of pulmonary hypertension and the treatment options.


Questions and Answers
  • 1. 
    Which of the following regarding pulmonary hypertension (PH) is FALSE?
    • A. 

      PH has many underlying etiologies

    • B. 

      The disease affects the left side of the heart

    • C. 

      The hemodynamic definition of PH is a mean pulmonary arterial pressure (PAP) greater than or equal to 25 mmHg

    • D. 

      Pulmonary arterial hypertension (PAH) is a subset of PH

  • 2. 
    • A. 

      The disease affects men much more than women

    • B. 

      Non-specific symptoms such as fatigue and edema present clinically

    • C. 

      Catheterization is required when PH is suspected

    • D. 

      Underlying causes and PCWP or LVEDP are evaluated

  • 3. 
    • A. 

      Vasoconstriction is an issue

    • B. 

      Vascular wall remodeling is an issue

    • C. 

      There is a cure for PAH

    • D. 

      The balance of vasoconstriction and vasodilation may indicate PAH

  • 4. 
    All of the following are true regarding calcium channel blockers (CCBs) in PAH EXCEPT
    • A. 

      CCBs have a selective effect on vascular smooth muscle

    • B. 

      Normal physiologic doses are sufficient for treatment purposes

    • C. 

      Adverse effects must be considered

    • D. 

      Long-term clinical response is less than 10%

  • 5. 
    • A. 

      The drug is a prostacyclin analog

    • B. 

      There are two products: Flolan and Veletri

    • C. 

      The drug improves mortality

    • D. 

      The drug is selective

  • 6. 
    Which of the following regarding treprostinil is FALSE?
    • A. 

      It has a longer half-life than epoprostenol

    • B. 

      It is also shown to have a survival benefit

    • C. 

      It has a higher cost than epoprostenol

    • D. 

      It is stable at room temperature without a need for a back-up cassette.

    • E. 

      It is a prostacyclin analog

  • 7. 
    Treprostinil, similar to epoprostenol, has two products.
    • A. 

      True

    • B. 

      False

  • 8. 
    Regarding iloprost, which of the following is FALSE?
    • A. 

      It is a prostacyclin analog

    • B. 

      It is approved for PAH WHO class 3 or 4 symptoms

    • C. 

      Very few doses are given per day

    • D. 

      There is a significant improvement in 6MWD and hemodynamics

  • 9. 
    • A. 

      It is an ET-1 receptor agonist

    • B. 

      It is safe to use in pregnant women

    • C. 

      It is highly selective for the endothelin A (ETa) receptor

    • D. 

      It has many drug interactions

  • 10. 
    Which of the following regarding ambrisentan is FALSE?
    • A. 

      It is a non-selective ETa antagonist

    • B. 

      Teratogenicity is an issue

    • C. 

      Drug interactions are still concerning

  • 11. 
    All of the following are true regarding macitentan EXCEPT
    • A. 

      It is safe to use in pregnant women

    • B. 

      It is a tissue selective ET-1 receptor antagonist

    • C. 

      Hepatotoxicity is a concern

    • D. 

      Drug interactions are a cocnern

  • 12. 
    Which of the following statements regarding the comparison between sildenfail and tadalafil in the context of PAH is FALSE?
    • A. 

      Sildenafil is shorter-acting while tadalafil is longer-acting

    • B. 

      Sildenafil is TID dosing while tadalafil is QD dosing

    • C. 

      Flushing and hypotension are two concerns with both drugs

    • D. 

      Exercise ability is improved with both drugs

    • E. 

      Nitrates can be safely used with both drugs

  • 13. 
    The following statements are true regarding riociguat EXCEPT
    • A. 

      It is a soluble guanylate cyclase (sGC) stimulator

    • B. 

      It can be used in patients with renal failure

    • C. 

      Teratogenicity and hepatotoicity are concerns

    • D. 

      There are many drug interactions

  • 14. 
    Which of the following correctly represents the target INR range for a patient with PAH on warfarin?
    • A. 

      1.0 - 2.0

    • B. 

      1.5 - 2.5

    • C. 

      2.0 - 3.0

    • D. 

      2.5 - 3.5

  • 15. 
    Which of the following regarding the treatment of PAH is FALSE?
    • A. 

      There is a large amount of long-term data for the therapies of PAH

    • B. 

      Prostacyclin dosage forms must be considered

    • C. 

      Costs and convenience must be considered

    • D. 

      Pharmacists are important in the therapy

  • 16. 
    What can pharmacists contribute in the therapy of PAH?
    • A. 

      Medication safety

    • B. 

      Optimizing medical regimens

    • C. 

      Patient education and adherence

    • D. 

      Quality improvement